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Abstract Background. High-dose chemoradiotherapy 
combined with autologous bone marrow transplantation 
can cure patients with disseminated, aggressive non- 
Hodgkin’s lymphoma in whom first-line chemotherapy 
has failed. In contrast, cure is rare with second-line che­
motherapy. It has been suggested that patients with slow 
responses to the initial phase of first-line chemotherapy 
are at high risk for relapse. Therefore, such patients are 
potential candidates for early bone marrow transplan­
tation.
Methods. To investigate whether patients with slow 
responses, defined as only a partial response after three 
courses of cyclophosphamide, doxorubicin, vincristine, 
and prednisone (CHOP), would benefit from early trans­
plantation, we conducted a prospective, randomized tri­
al. The early application of high-dose chemoradiothera­
py and autologous bone marrow transplantation was 
compared with the continuation of CHOP therapy for an­
other five courses. Patients with complete responses af­
ter three courses of CHOP (fast responses) and patients 
who responded partially but still had tumor-positive mar­
row continued with another five courses of CHOP. The
COMBINATION chemotherapy can cure about 45perccnt of patients with disseminated intermedi- 
ate-grade or high-grade non-Hodgkin’s lymphoma.1 
Several institutions have reported that aggressive regi­
mens of chemotherapy containing six to eight drugs 
gave better results than the CHOP regimen (which 
contains cyclophosphamide, doxorubicin, vincristine, 
and prednisone),2'7 but in two large, multicenter, ran-
From the Department of Hematology, University Hospital, Utrecht (L.F.V,, 
A.W.D., G.C.G.); the Dr. Daniel den Hoed Cancer Center, Rotterdam (W.L.J.P., 
A.H., B.L.); the Department of Hematology and Oncology, University Hospi­
tal, Maastricht (H.C.S.); the Department of Hematology, University Hospital, 
Rotterdam (P.S., B.L.); the Department of Hematology, University Hospital, Gro­
ningen (G.W.I.); the Department of Hematology, University Hospital, Leiden 
(H.C.K.-N.); the Department of Hematology, University Hospital, Nijmegen 
(J.M.M.R.); the Department of Hematology, Academic Medical Center, Amster­
dam (R.H.J.O.); and the Department of Hematology, Leyenburg Hospital, the 
Hague (H.L.H.) —  all in the Netherlands; and the Department of Oncology and 
Hematology, Free University, Brussels, Belgium (R.S.). Address reprint requests 
to Dr. Verdonck at the University Hospital Utrecht, Department of Hematology 
(G03.647), P.O. Box 85.500, 3508 GA Utrecht, the Netherlands.
Supported by a grant (OG 89-028) from the Commission on Investigative Med­
icine of the Dutch National Health Insurance Board.
study end points were the response rate, overall surviv­
al, disease-free survival, and event-free survival.
Results. Of 286 patients who could be evaluated for the 
rapidity of their response after three courses of CHOP, 38 
percent had fast responses, 47 percent had slow respons­
es, and 15 percent had no response. Among 106 patients 
with slow responses who had lymphoma-negative marrow, 
69 patients (65 percent) were randomized. Seventy-four 
percent of the CHOP group and 68 percent of the transplan­
tation group had complete remissions (P-0.54). At four 
years the rates of overall, disease-free, and event-free sur­
vival were 85, 72, and 53 percent, respectively, in the 
CHOP group and 56, 60, and 41 percent in the transplan­
tation group (P>0.10). The disease-free survival in both 
groups did not differ significantly from that of nonrandom­
ized patients with fast responses (54 percent at four years).
Conclusions. The early application of high-dose, mar­
row-ablative chemoradiotherapy with autologous bone 
marrow transplantation does not improve the outcome in 
patients with aggressive non-Hodgkin’s lymphoma that 
responds slowly to first-line CHOP chemotherapy. (N Engl 
J Med 1995;332:1045-51.)
domized, phase 3 trials8,9 the more aggressive regimens 
were not found to be superior to CHOP, which is wide­
ly used as first-line chemotherapy for non-Hodgkin’s 
lymphoma. However, CHOP fails to cure the disease 
when remissions are incomplete or unstable. Retreat­
ment of patients who have relapsed with second-line, 
so-called salvage chemotherapy is generally unsuccess­
ful.10 High-dose chemoradiotherapy with autologous 
bone marrow transplantation may, however, cure some 
of these patients if they have disease that responds to 
chemotherapy.1(Ma
Early in the course of treatment, or even at diagno­
sis, it is important to identify patients who are unlikely 
to have complete remissions. These high-risk patients 
may benefit from high-dose chemoradiotherapy with 
bone marrow transplantation while their lymphomas 
can still respond to first-line chemotherapy. It has been 
suggested that patients in whom complete remission 
occurs rapidly with first-line chemotherapy — i.e., 
within three cycles of conventional chemotherapy —
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have a better chance of cure than patients who respond
more slowly.19,20
In 1987 wc began assessing the efficacy of high-dose 
marrow-ablative therapy combined with autologous 
bone marrow transplantation in patients with dissemi­
nated, aggressive non-Hodgkin’s lymphoma who have 
slow responses to chemotherapy. All patients were 
treated with CHOP, and their responses were evaluat­
ed after three courscs. Those with partial responses 
were considered to have slow responses, and those with 
complete responses after three courses of CHOP were 
considered to have fast responses. We report here the 
results of a multicenter study in which patients with 
slow responses and lymphoma-negative bone marrow 
were eligible for random assignment to either another 
five courses of CHOP (the standard regimen) or mar­
row-ablative chemoradiotherapy with autologous bone 
marrow transplantation.
M e t h o d s
Between January 1987 and April 1994, we enrolled 320 patients in 
the study. Patients from 15 to 60 years of age were eligible if they had 
measurable, biopsy-confirmed intermediate-grade or high-grade non- 
Hodgkin’s lymphoma (groups D through H, according to the classi­
fication system of the Working Formulation),21 including unelassi- 
iiable intermediate-grade and high-grade lymphoma, and stage II,
III, or IV disease according to the Ann Arbor classification. The B or 
T  immunotype was determined in either snap-frozen or paraffin- 
embedded tissue with mouse monoclonal antibodies against B-cell 
antigens CD20 and MB2 and T-cell antigens CD3 and CD45, 
Patients were determined to be ineligible if they had previous che­
motherapy or radiotherapy; a history of low-grade malignant lym­
phoma; group I or J  high-grade cancer; prior cancer, except non-mel­
anoma skin cancer or cervical carcinoma stage I; a positive serologic 
test for the human immunodeficiency virus; involvement of the cen­
tral nervous system by lymphoma; or severe cardiac, pulmonary, neu­
rologic, or metabolic disease. Informed consent was obtained from all 
patients. The pathology slides for 88 percent of the patients under­
went central pathology review'. The protocol was approved by the in­
stitutional review board of each center.
Staging of the extenL of disease, performed before therapy, includ­
ed a history taking and physical examination; complete blood counts, 
including a search for abnormal lymphoid cells in the blood by mor­
phologic and immunologic studies using flow cytometry; tests of renal 
and liver function; determination of the erythrocyte sedimentation 
rate; measurement of serum albumin and scrum electrolytes; protein 
electrophoresis and immunoclcctrophoresis; measurement of serum 
lactate dehydrogenase (upper limit, 250 U per liter); chest radiogra­
phy; computed tomography of the abdomen and thorax; consultation 
with an ear, nose, and throat specialist; and bone marrow biopsy and 
aspiration from the iliac crest, including immunophenotyping by im- 
munoperoxidase. As clinically indicated, lumbar puncture or liver bi­
opsy was performed.
Complete restaging of each patient’s condition was performed af­
ter three courses of CHOP chemotherapy and after the completion 
of therapy. During follow-up, staging procedures were repeated in 
their entirety at least every six months for the first three years and 
thereafter as clinically indicated.
O f the 320 patients enrolled, 34 patients were not eligible for the 
following reasons: they did not meet the criteria for entry into the 
study (6 patients), they had localized disease (5 patients), they had 
been treated before registration (2 patients), they had severe concom­
itant disease (4 patients), or the diagnosis was not confirmed (17 pa­
tients). Thus, 286 patients were eligible for analysis.
Treatment Protocol
CHOP was administered every 21 days as follows: 750 mg of cyclo­
phosphamide per square meter of hody-surface area intravenously on 
day 1; 50 mg of doxorubicin per square meter intravenously on day 1;
1.4 mg of vincristine per square meter intravenously on day 1 (maxi­
mal dose, 2.0 mg); and 100 mg of prednisone orally on days 1 through
5. Dose reductions were made as previously described if there was 
hematologic toxicity"; however, the first course was given in full. If 
there w'as mild neurotoxicity (i.e., paresthesias or decreased tendon 
reflexes), the dose of vincristine was reduced to 50 percent, and if 
there was severe neurotoxicity (i.e., marked loss of motor function), 
the vincristine was omitted. All patients were to receive three courses 
of CHOP and were then to be evaluated for their response.
To assess the response to CHOP, all tests that had abnormal re­
sults on staging before therapy were repeated. Complete remission 
was defined as the disappearance of all clinical evidence (physical 
and radiographic) of disease. Lymph nodes less than I cm in diame­
ter on radiography were considered uninvolved. Patients with residu­
al abnormalities detected with computed tomography, especially pa­
tients with bulky disease (tumor ^ 1 0  cm) at diagnosis, were not 
considered to be in complete remission unless the abnormality had 
decreased in size by 90 percent or more or unless biopsy proved it to 
be uninvolvcd. Partial remission was defined as a reduction by at 
least 25 percent of the sum of the largest tumor diameters. Progres­
sive disease was defined as an increase of at least 25 percent in the 
size of the original tumor mass or as the development of new lesions. 
Patients w-ho did not meet any of the preceding definitions were clas­
sified as having no response.
When they had completed the evaluation after the third cycle of 
CHOP, patients with partial remissions and no bone marrow infiltra­
tion were asked about entering the trial. Those who agreed to do so 
were randomized. The patients randomly assigned to transplantation 
underwent bone marrow' collection as soon as complete marrow re­
population had occurred. They were given a fourth course of CHOP 
the day after the collection. They then received high-dose chemother­
apy, radiation, and infusion of autologous marrow'.
Patients randomly assigned to CHOP began their fourth course on 
schedule. Those who had complete remissions and those with partial 
responses but with marrow' involvement were treated with five addi­
tional courses of C H O P  Patients who had no response or whose dis­
ease progressed were not studied further and were given other ther­
apy at the discretion of the investigators.
Bone marrow collection and cryopreservation were performed as 
soon as the marrow was repopulated after the third course of 
GHOP.Vi At least 2X10H nucleated cells per kilogram of body weight 
were collected, Reference samples of cells were frozen in small am­
pules and thawed during the first week after freezing in order for the 
investigators to check the quality of cryopreservation (with myeloid 
and erythroid colony growth in vitro). The absence of marrow in­
volvement by the lymphoma was checked again at the time of the 
marrow collection by histologic and cytologic methods, None of the 
patients assigned to transplantation had detectable marrow involve­
ment at the time of the marrow collection.
So that there would be time after the collection to evaluate the 
quality of the marrow graft and prepare for transplantation, the pa­
tients randomly assigned to transplantation received a fourth course 
of CHOP immediately after the bone marrow collection. The condi­
tioning regimen lor transplantation was scheduled to be carried out 
w'ithin six weeks after the fourth course of CHOP,
The high-dose chemoradiotherapy administered before the reinfu­
sion of autologous marrow consisted of cyclophosphamide (60 mg per 
kilogram, infused on each of two consecutive days), followed two days 
later by total-body irradiation (800 cGy in one fraction). The autol­
ogous (unpurged) marrow graft was thawed rapidly and reinfused 
through a central venous catheter the day after the total-body irra­
diation.
Statistical Analysis
The study was designed on the assumption that for paLients in par­
tial remission after three courses of CHOP, two-year event-free surviv­
al would be improved from 35 percent with the continuation of CHOP 
to 70 percent with bone marrow transplantation, which would mean an 
improvement for patients with slow' responses so that their outcome 
would be equivalent to that of patients with fast responses.19 Therefore, 
a total of 60 patients had to be randomly assigned to the two treat­
ments lor the study to have a power of 80 percent to detect such a dil- 
ference with a one-sided test at a significance level of 0.05. It w'as ex­
pected that 25 percent of the patients would have partial remissions 
without marrow infiltration after three courses of CHOP. Thus, accord­
ing to estimates before the study began, about 240 patients had to be 
enrolled for the induction treatment with CHOP in order to meet the
Vol. 332 No. 16 CHO P VS. BONE MARROW TRANSPLANTATION FOR NON-HODGKIN’S LYMPHOMA 1047
CHARACTERISTIC
objective of GO randomized patients. Eventual­
ly, 286 eligible patients were enrolled, 106 of 
whom (37 percent) had partial remissions 
without marrow infiltration and 69 of whom 
(24 percent) were randomized.
No further patients were admitted to the 
study alter December 31, 1993. The data 
were analyzed in April 1994, with the last fol- 
low-up data available for all patients still 
alive, except two patients (not randomized) 
who were lost to follow-up after one year. The 
median duration of follow-up for the 181 pa­
tients still alive at the final update was three 
years (range, two months to seven years). Six­
ty-one patients had follow-up of more than 
four years.
Logistic-rcgrcssion analysis, univariate and 
multivariate, was used to test and determine 
the strength of the association between the 
probability of complete remission and prog­
nostic factors and to determine the difference 
between the treatment groups. In these anal­
yses, only complete remissions in patients 
treated according to the protocol were con­
sidered —  i.e., complete remission after three 
courses of CHOP, after continuing treatment 
with CHOP, or after bone marrow transplan­
tation for patients in partial remission after 
the first three cycles ol CHOP. Patients 
whose complete remissions occurred only lat­
er, with second-line treatment, were classified 
as hav ing  no  com ple te  remission.
The a c tu a r ia l  method of Kaplan and Meier 
was used to ca lcu la te  probabilities of survival.
Cox regression analysis was used for statisti­
cal tests and the analysis of prognostic fac­
tors. The following end points were analyzed: 
overall survival, with failure defined as death 
from any cause; disease-free survival, which 
was restricted to patients entering complete 
remission while being treated according to 
the protocol, with failure defined as relapse or 
death during a first complete remission; and 
event-free survival, with failure defined as no 
complete remission during treatment accord­
ing to the protocol, relapse after a complete 
remission, or death during a first complete re­
mission. Time was measured from the start 
of the first treatment with C H O P or, in the 
comparison of the randomized treatment 
groups, from the time of randomization. Dis- 
ease-free survival was measured from the 
date of complete remission. From the esti­
mate of the relative death rate (R) in the 
transplantation (ABMT) group as compared 
with the C H O P group, obtained from the 
Cox model, the corresponding difference in 
overall survival (OS) between the two groups 
(OSABMT— OS(;HO,>) was calculated by the for­
mula OSAI,MT =  O S,\ în(,j,. In this formula, the 
overall survival after C H O P therapy was set 
at 70 percent. The 95 percent: confidence
interval for this difference in survival was calculated by substituting 
ibr 11 the 95 percent confidence intervals of the estimated relative 
death rate.
The following variables were included in the analysis of prognostic 
factors: age, sex, histologic grade of cancer (i.e., intermediate vs. 
high), Ann Arbor stage, number of extranodal sites, bone marrow 
involvement, bulky disease, immunologic phenotype, serum concen­
tration of lactate dehydrogenase, and performance status (assessed 
according to the classification system of the World Health Organiza­
tion). For all the statistical tests, a significance level of 0.05 was used. 
All reported P values are two-sided and unadjusted.
Interim analyses with rules for stopping in the event of extreme 
differences in outcome favoring the transplantation group were 
planned and performed twice during the study. The statistical crite-
Table 1. Characteristics of the 286 Patients According to Their Responses after Three
Courses of CHOP Chemotherapy,*
R e s p o n s e  a n d  R a n d o m i z a t i o n  S t a t u s
COMPLETE
REMISSION PARTIAL REMISSION,
PARTIAL 
REMISSION, 
NONRAN- 
DOMIZRD
PARTIAL
REMISSION,
MARROW
INVOLVE­
MENT
PROGRES­
SION 
OR NO 
RESPONSE
A l l ,
PATIENTS
(N -  110) RANDOMIZED (N  = .17) (N - 2 7 ) ( N -  4} ) (N - 2 B 6 )
CHOP 
(n — 35)
Trans­
plantation
(n = 3 4 )
percentage o f patients in group
Sex
Male 64 63 56 54 70 74 64
Female 36 37 44 46 30 26 36
Tumor histologyf
Follicular, large cell 5 17 4 8 26 7 9
Diffuse, small clcaved cell 4 3 3 5 19 12 6
Diffuse, mixed 11 14 23 8 33 21 16
Diffuse, large cell 39 26 38 40 11 23 33
Unclassifiable, intermediate 4 3 9 10 4 3 5
grade
Immunoblastic 34 20 20 24 7 26 25
Unclassifiable, high grade 3 17 3 5 0 9 6
Stage
II 53 43 50 35 0 23 40
III 24 26 18 24 0 14 20
IV 23 31 32 41 100 63 40
Extranodal sites (no.)
0 64 49 50 57 48 30 53
1 23 37 35 16 23 42 28
2 -4 13 14 15 27 29 28 19
Bone marrow involvement
No 93 94 89 91 0 67 80
Yes 7 6 11 9 100 33 20
Immunologic phenotype
B-cell 64 77 79 62 67 67 68
T-cell 20 3 9 24 11 19 16
Neither 3 Ü 0 0 0 0 1
Unknown 13 20 12 14 22 14 15
B symptoms
Absent 60 68 56 51 63 42 57
Present 40 32 44 49 37 58 43
Lactate dehydrogenase (U/liter)
<250 42 17 20 27 26 23 30
250 to <750 51 59 62 62 67 49 56
2*750 7 24 18 11 7 28 14
Bulky disease (tumor ^ 1 0  cm)
No 76 54 1 41 59 63 69 65
Yes 24 46 59 41 37 31 35
Performance status^
0 49 43 38 46 56 33 45
1 43 51 53 41 41 39 44
2 -4 8 6 9 13 3 28 11
International Index§ 
Low 25 3 9 10 0 7 13
Low intermediate 43 53 47 38 26 30 40
High intermediate 28 41 41 41 70 37 39
High 4 3 3 11 4 26 8
*Thc median age of the patients was 45 years (range, 15 to 60). 
tA ccord ing  to the classification system of the Working Formulation.31 
|A ccord ing  to the classification system of the World Health Organization.
§As defined by the International Non-Hodgkin's Lymphoma Prognostic Factors Project,2,1
rion for stopping the accrual of patients was an improvement in over­
all survival in the transplantation group that was statistically signif­
icant at the level of P<0.005. Because of this stringent criterion, no 
adaptation of the nominal significance levels at the final evaluation 
was required.
R e s u lt s
Response after Three Courses of CHOP Chemotherapy
Table 1 shows the characteristics of all 286 eligible 
patients at diagnosis and the subgroups of patients ac­
cording to their responses after three courses of CHOP. 
Among the 286 patients, 110 (38 percent) had com-
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plcte remissions after the first three courses of CHOP, 
133 (47 percent) had partial remissions, and 43 (15
percent) had either no response or progression of dis­
ease (Table 2). Of the 133 patients who had partial re­
sponses, 27 still had lymphoma in the bone marrow 
and were therefore ineligible for randomization. Thus, 
106 patients qualified for randomization, and 69 of 
them ((55 percent) were randomized. Thirty-seven 
patients (35 percent) were not randomized for the fol­
lowing reasons: refusal by the patient (22 patients), 
psychological reasons (4), medical reasons (5), and ad­
ministrative errors (6).
Response of the Randomized Patients
Table 1 shows the clinical features of the patients 
randomly assigned to CHOP or bone marrow’ trans­
plantation. The two groups were well balanced, espe­
cially with regard to the prognostic variables defined by 
the international index established by the International 
Non-Hodgkin’s Lymphoma Prognostic Factors Proj­
ect.'^ At randomization, 35 patients were assigned to 
continue standard treatment with CHOP, and 34 pa­
tients were assigned to transplantation. Howevez*, eight 
patients assigned to the transplantation group did not 
proceed to that treatment; three declined the treat­
ment, and five had progressive disease. Of the patients 
assigned to CHOP who continued that treatment, sev­
en patients did not complete all eight courses because 
of progressive disease.
The conditioning regimen for transplantation was 
started a median of 27 days (range, 17 to 60) after the 
fourth course of CHOP. In fact, 26 of 28 patients start­
ed the conditioning regimen within 39 days after the 
fourth course of CHOP. The results were analyzed on 
an intention-to-treat basis. Twenty-six of the 35 pa­
tients (74 percent) randomly assigned to CHOP had 
complete remissions, as compared with 23 of the 34- 
patients (68 percent) randomly assigned to transplan­
tation (Table 2). This difference was not significant 
(P = 0.54). The exclusion of the 15 patients who did not 
complete the treatment as planned could have biased 
the outcome, because 12 of these patients had early 
progressive disease. Analysis according to actual treat-
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Figure 1. Overall Survival from the Time of Randomization, Ac­
cording to Treatment Group.
Among 35 patients assigned to receive eight courses of CHOP 
and 34 patients assigned to receive high-dose che mo radiother­
apy and autologous bone marrow transplantation, there were
6 and 12 deaths, respectively.
Table 2. Treatment Outcome According to the Response after Three Courses of
CHOP Chemotherapy.*
VAUIAIll. li R e s p o n s e  a n d  R a n d o m i z a t i o n  S t a t u s
PARTIAL PARTIAL
REMISSION, REMISSION, PROGRESSION
COMPLETE NONRAN- MARROW OR NO
REMISSION PARTIAL nOM IZED INVOLVEMENT RESPONSE
(N  -  \ 10) REMISSION, RANDOMIZED (N = 3 7 ) (N - 2 7 ) (N  -  4 3 )
Trans- I
CHOP plamation
(n =  35) (n =  34)
fio, (»/'/»({fjerifx
Coniplele remission after CHOP or NA 26 23 23 10 NA
transplantation ♦
Relapse after complete remission 44 6 7 5 4 NA
Death 35 6 12 14 9 29
Treatment-related toxic effects 4 0 2 2 3 1
Lymphoma 30 6 10 11 4 23
Other 1 0 0 1 2 5
*NA denotes not applicable.
ments did not change the results; among the 28 pa­
tients in the CHOP group who completed eight courses 
of CHOP, 26 reached complete remission, 6 relapsed, 
and only 1 died, whereas among the 26 patients in the 
transplantation group who underwent transplantation, 
23 reached complete remission, 7 relapsed, and 9 died.
Survival of the Randomized Patients
The mean (±SE) estimated overall survival four 
years from randomization was 85±6 percent in the 
CHOP group and 56±10 percent in the transplanta­
tion group (Fig. 1). Disease-free survival at four years 
was 72±10 percent in the CHOP group and 60±12
percent in the transplantation group. Event-free surviv­
al at four years was 53 ± 9  percent in the CH O P group 
and 41 ±10 percent in the transplantation group (Fig. 
2). There were no significant differences between the 
two treatment methods in overall survival (hazard
ratio for transplantation vs. CHOP, 2.2; 95 percent 
confidence interval, 0.82 to 5.9; P =  0.12), disease-free 
survival (hazard ratio, 1.5; 95 percent confidence inter­
val, 0.49 to 4.3; P =  0.50), or event- 
free survival (hazard ratio, 1.3; 95 
percent confidence interval, 0.66 to
2.61; P =  0.43). Six patients in the 
CH O P group and seven patients in 
the transplantation group relapsed. 
Six patients assigned to the CH O P 
group died, all of lymphoma, where­
as 12 patients in the transplantation 
group died, 10 of lymphoma and 
2 of treatment-related toxic effects.
Response of the Nonrandomized 
Patients
The 110 patients in complete re­
mission, the 27 patients with partial 
responses and marrow involvement, 
and the 37 nonrandomized patients
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Figure 2. Event-free Survival from the Time of Randomization,
According to Treatment Group.
Among 35 patients assigned to receive eight courses of CHOP 
and 34 patients assigned to receive high-dose chemoradiother- 
apy and autologous bone marrow transplantation, there were 15
and 18 treatment failures, respectively.
with partial responses but no marrow involvement 
were all scheduled to continue with another five courses 
of CHOP (Table 2). Among the 110 patients in com­
plete remission, 44 patients (40 percent) relapsed dur­
ing CHOP treatment or thereafter. Among the 27 pa­
tients with partial responses but with bone marrow 
involvement, 10 patients (37 percent) had complete re­
missions. The rate of' complete remission in these pa­
tients was significantly lower (P =  0.006) than that in 
the patients who had partial remissions but who had no 
marrow infiltration. Among the 37 nonrandomized pa­
tients with partial responses and no bone marrow in­
volvement, 23 (62 percent) had complete remissions 
during CHOP therapy. For these 37 patients, overall, 
disease-free, and event-free survival at four years was
55, 70, and 43 percent, respectively.
Survival of the Eligible Patients
Among all 286 study patients, actuarial overall sur­
vival at four years was 59 ±3 percent (Fig. 3), and for 
the 192 patients with complete responses disease-free 
survival at four years was estimated to be 58±3 per­
cent. For the nonrandomized group of patients with 
last responses (those in complete remission after three 
courses of CHOP), disease-free survival at four years 
was 54-±5 percent. Table 2 shows the causes of death 
in the various treatment groups. Figure 4 shows that 
there was no significant difference in survival between 
patients in complete remission after three courses of 
CHOP (those with fast responses) and patients with 
partial (slow) responses. The outcome in patients with 
either no response or progressive disease was signifi­
cantly worse (P<0.001) than in patients who had com­
plete or partial remissions.
Analysis of Prognostic Factors
Multivariate analysis showed that for all eligible pa­
tients enrolled in the study, the following prognostic 
factors were predictive of overall survival: Ann Arbor
stage (II vs. III vs. IV; P<0.001), histologic grade of 
cancer (intermediate vs. high; P = 0.01), serum concen­
tration of lactate dehydrogenase (<750 vs. ^750 U per 
liter; P<0.001), and performance status (0 or 1 vs. 2, 3, 
or 4; P<0.001). Other prognostic factors did not have 
additional predictive value. Except for the grade of can­
cer, these prognostic factors agree with those defined by 
the international index.23 Adjustment for these factors 
did not affect the nonsignificant differences between 
the randomized treatment groups.
D is c u s s io n
We assessed the value of early intervention with 
high-dose, marrow-ablative chemoradiotherapy and au­
tologous bone marrow transplantation in patients with 
disseminated, aggressive non-Hodgkin’s lymphoma who 
had slow responses to standard CHOP chemotherapy. 
There were no significant differences in the rates of 
complete remission, estimated overall survival, disease- 
free survival, and event-free survival between patients 
who received bone marrow transplantation and those 
who continued with the conventional therapy.
The number of patients randomized was only suffi­
cient to show the expected difference in outcome of 35 
percent between the two treatment methods, The rela­
tive risk of death in the transplantation group as com­
pared with the CHOP group was 2.2 (95 perccnt con­
fidence interval, 0.8 to 5.9). This value corresponds to 
a difference in the probability of overall survival of —23 
percent (95 percent confidence interval, +5  percent to 
—58 percent), if a 70 percent probability of long-term 
overall survival in the CHOP group is assumed. This 
result implies that a small benefit of transplantation 
cannot be excluded, but any substantial benefit is ex­
tremely unlikely. Considering the cost of bone marrow 
transplantation and the failure of this very intensive 
treatment to improve overall survival and disease-free 
survival, we conclude that the early use of transplanta­
tion in patients with slow responses is not useful. It re­
mains to be clarified whether autologous bone marrow 
transplantation may have a role among patients in the 
recently defined high-risk subgroup of the international
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Figure 3. Overall Survival among All Eligible Patients from the
Start of the First Course of CHOP.
Among 286 eligible patients, there were 105 deaths.
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Figure 4. Overall Survival from the Time of Evaluation among All 
Eligible Patients, According to the Response after Three Cours­
es of C HO P.
P R - denotes partial remission without bone marrow involve­
ment, PR+ partial remission with bone marrow involvement, CR 
complete remission, and NR progressive disease
or no response.
index who have very poor survival after conventional 
first-line chemotherapy or among patients with a re­
sponse but with proved residual disease after first-line 
chemotherapy.
When our study began, it was suggested that patients 
with aggressive non-Hodgkin’s lymphoma1E),2ii or other 
hematologic cancers24,25 who had complete responses 
rapidly might have a better probability of cure than 
those with slower responses to chemotherapy. A recent 
comprehensive review of several phase 2 studies sup­
ports this hypothesis.2*1 The ability to stratify patients 
early in the course of disease as being at either high or 
low risk appears clinically important; high-risk patients 
may benefit from experimental approaches such as 
high-dose therapy with transplantation, whereas low- 
risk patients should not receive unusually hazardous 
treatments. With its international index, the Interna­
tional Non-Hodgkin’s Lymphoma Prognostic Factors 
Project has defined factors present at diagnosis that 
distinguish patients in groups with good, intermediate, 
or poor survival.21 The value of these prognostic factors 
was confirmed in our study; application of the interna­
tional index to ail study patients gave probabilities of 
four-year overall survival comparable to those reported 
by the international index,23 ranging from 78 percent in 
the low-risk group to 24 percent in the high-risk group 
(data not shown).
Although 106 patients were eligible for random as­
signment to transplantation or to another five courses 
of CHOP, only 69 patients (65 percent) were actually 
randomized. Thus, 37 patients were not randomized, 
mainly because the patients declined randomization. 
There were no significant differences in rates of com­
plete remission or overall, disease-free, or event-free 
survival between patients who were randomly assigned 
to the two treatment groups, or among the two groups 
and the 37 nonrandomized patients who also received 
five more courses of CHOP. In fact, the estimated rates
of disease-free and event-free survival at four years 
were 72 and 53 pcrcent, respectively, for the random­
ized CHOP group and 60 and 41 percent for the trans­
plantation group, as compared with 70 and 43 percent 
for the 37 nonrandomized patients. Procedure-related
deaths occurred in 6 percent of the transplantation 
group; mortality was similar (5 pcrcent) in the nonran­
domized CHOP groups. Probably by chance, proce­
dure-related deaths did not occur in the randomized 
CHOP group. Furthermore, 54 percent of the nonran­
domized group of patients with fast responses (those in 
complete remission after three courses of CHOP) who 
continued with another five courses of CHOP were 
alive without disease at four years. Thus, those who re­
sponded slowly did as well as those who responded rap­
idly. Apparently, it was the fact that they had complete 
remissions that was predictive of outcome, rather than 
the time required to attain them. Although most phase 
2 studies of the value of a rapid response reported that 
the speed with which patients achieved complete remis­
sions was an important prognostic factor, l9»21,»2(l two 
studies could not confirm this finding.21’ This discrep­
ancy may be caused by the follow-up periods, which 
were relatively short in most of these studies.
We are aware of only two other studies in which 
high-dose therapy and autologous bone marrow trans­
plantation were compared with chemotherapy in 
patients with aggressive non-Hodgkin’s lymphoma. In 
these studies transplantation was not used early, but 
was applied after the completion of conventional che­
motherapy. A multicenter Italian study27 compared 
high-dose chemotherapy and transplantation with sal­
vage chemotherapy in patients who were in partial 
remission after the completion of first-line chemothera­
py. The results suggested a better disease-free survival 
for the transplantation group. A multicenter French 
study211 compared intensive, but not mar row-ablative, 
chemotherapy and bone marrow transplantation with 
intensive sequential chemotherapy in patients who were 
in complete remission after first-line chemotherapy. 
This study found no difference in disease-free survival 
between the two treatments. Although both studies dif­
fer from this one on several points, their data suggest 
that high-dose therapy combined with bone marrow 
transplantation does not improve outcome in patients 
who are in either very good partial remission (with re­
sidual abnormalities of unknown importance) or com­
plete remission after chemotherapy.
We conclude that the early use of marrow-ablative 
chemoradiotherapy with autologous bone marrow trans­
plantation offers no significant benefit in patients with 
aggressive non-Hodgkin’s lymphoma who have re­
sponded slowly to first-line cheinotherapy. Further­
more, the rapidity with which complete remission is 
achieved appears to have no prognostic importance.
We arc indebted to Jan  A.M. van Unnik for skillful central pathol­
ogy review, to Mar g net Bongers for central data management, to the 
Comprehensive Cancer Centers in the Netherlands for assistance 
with data management, to Piet van Assendelft for the construction of 
a data base, and to Joukje van der Velde for assistance in the prepa­
ration of the manuscript.
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